Skip to main content

Opti: New microbial strain registrations

Opti: New microbial strain registrations

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the registration of five new microbial strains under the Budapest Treaty. This increases the number of strain registrations from three to eight.

The Budapest Treaty is an international treaty administered by the World Intellectual Property Organisation which enables the deposition of micro-organisms for the purposes of patent protection. This provides a reference point for filing and defending patents and establishing title during commercial discussions. Registration of these strains protects the advances made in developing novel sugars using OptiBiotix’s proprietary OptiBiotic® platform technology.

The five strains have been identified as having the potential to generate novel oligosaccharides (carbohydrates that consist of a small number of sugars). As announced on 9 July 2015, oligosaccharides from strains showing commercial potential are being scaled up, purified, and tested for their organoleptic (taste, texture, aftertaste) and microbiome modulating properties. This work is the final stages of the laboratory programme which will enable OptiBiotix to progress its pipeline of novel oligosaccharides to testing in human studies.

Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the registration of these strains which will protect the recent advances we have made in developing novel sugars. With our cholesterol product moving to pilot manufacture and our sugar development programmes moving towards clinical studies, we are making good progress in multiple product and partnering opportunities for compounds which modify the human microbiome to improve human health.”